ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology

27

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 /PRNewswire/ — ORIC Pharmaceuticals (“ORIC”), a privately held oncology company focused on the discovery and development of drugs to address treatment resistant cancers, announced today that the first subject in a Phase 1a clinical study has…


https://www.prnewswire.com/news-releases/oric-pharmaceuticals-announces-first-subject-dosed-in-phase-1-clinical-study-of-novel-gr-antagonist-with-planned-development-for-oncology-300544631.html